Lonza Group announced to increase the number of human stem cells it offers by supplying big batch sizes of CD34+ hematopoietic stem cells from human cord blood to expand cohorts for greater capacity and easier HLA-matched model development.
Regen BioPharma, Inc. Announced the introduction of a novel immunotherapy approach using chimeric antigen receptor (CAR) natural killer (NK), macrophage (M), and T cells (T) to overcome the challenges associated with T cell fatigue in existing strategies and enable these cell therapies to successfully target solid tumors.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3937
Published Date: Nov 01, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising prevalence of leukemia and the growing advancements in stem cell transplantation technology are the major factors driving the growth of the market.
The market size of hematopoietic stem cells transplantation is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., CSG-BIO Company, Inc. (CellSave), CBR Systems, Inc., Pluristem Inc., Global Cord Blood Corporation, ViaCord, LLC, Cynata Therapeutics Limited, and others.
The autologous segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.